GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dianthus Therapeutics Inc (NAS:DNTH) » Definitions » Gross Margin %

Dianthus Therapeutics (Dianthus Therapeutics) Gross Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Dianthus Therapeutics Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Dianthus Therapeutics's Gross Profit for the three months ended in Mar. 2024 was $0.87 Mil. Dianthus Therapeutics's Revenue for the three months ended in Mar. 2024 was $0.87 Mil. Therefore, Dianthus Therapeutics's Gross Margin % for the quarter that ended in Mar. 2024 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Dianthus Therapeutics's Gross Margin % or its related term are showing as below:


DNTH's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.88
* Ranked among companies with meaningful Gross Margin % only.

Dianthus Therapeutics had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Dianthus Therapeutics was 0.00% per year.


Dianthus Therapeutics Gross Margin % Historical Data

The historical data trend for Dianthus Therapeutics's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dianthus Therapeutics Gross Margin % Chart

Dianthus Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Gross Margin %
- - -

Dianthus Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Gross Margin % Get a 7-Day Free Trial - - - - -

Competitive Comparison of Dianthus Therapeutics's Gross Margin %

For the Biotechnology subindustry, Dianthus Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dianthus Therapeutics's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dianthus Therapeutics's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Dianthus Therapeutics's Gross Margin % falls into.



Dianthus Therapeutics Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Dianthus Therapeutics's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=2.8 / 2.826
=(Revenue - Cost of Goods Sold) / Revenue
=(2.826 - 0) / 2.826
=N/A %

Dianthus Therapeutics's Gross Margin for the quarter that ended in Mar. 2024 is calculated as


Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=0.9 / 0.874
=(Revenue - Cost of Goods Sold) / Revenue
=(0.874 - 0) / 0.874
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Dianthus Therapeutics  (NAS:DNTH) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Dianthus Therapeutics had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Dianthus Therapeutics Gross Margin % Related Terms

Thank you for viewing the detailed overview of Dianthus Therapeutics's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Dianthus Therapeutics (Dianthus Therapeutics) Business Description

Traded in Other Exchanges
Address
7 Times Square, 43rd Floor, New York, NY, USA, 10036
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is comprised of an experienced team of biotech and pharma executives who are leading the next generation of antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune diseases.

Dianthus Therapeutics (Dianthus Therapeutics) Headlines